Steward Partners Investment Advisory LLC Has $202,000 Stock Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Steward Partners Investment Advisory LLC grew its holdings in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 61.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 27,184 shares of the company’s stock after buying an additional 10,320 shares during the period. Steward Partners Investment Advisory LLC owned approximately 0.07% of Lifecore Biomedical worth $202,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Bank of New York Mellon Corp boosted its stake in Lifecore Biomedical by 71.9% during the fourth quarter. Bank of New York Mellon Corp now owns 80,572 shares of the company’s stock worth $599,000 after acquiring an additional 33,690 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Lifecore Biomedical by 125.9% during the 4th quarter. Rhumbline Advisers now owns 55,723 shares of the company’s stock worth $414,000 after purchasing an additional 31,056 shares in the last quarter. ARS Investment Partners LLC bought a new position in shares of Lifecore Biomedical during the 4th quarter worth about $74,000. MassMutual Private Wealth & Trust FSB bought a new position in Lifecore Biomedical in the fourth quarter worth approximately $209,000. Finally, 272 Capital LP boosted its holdings in Lifecore Biomedical by 511.1% in the third quarter. 272 Capital LP now owns 143,480 shares of the company’s stock worth $707,000 after acquiring an additional 120,002 shares in the last quarter. 83.36% of the stock is currently owned by institutional investors.

Lifecore Biomedical Stock Up 1.7 %

LFCR opened at $6.47 on Friday. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The company’s 50-day moving average is $6.07 and its 200 day moving average is $6.04. Lifecore Biomedical, Inc. has a fifty-two week low of $3.68 and a fifty-two week high of $7.99. The firm has a market capitalization of $239.55 million, a P/E ratio of -11.55 and a beta of 0.96.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. Research analysts expect that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on LFCR shares. Stephens reiterated an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a report on Friday, January 3rd. Craig Hallum lifted their price objective on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd.

Insider Buying and Selling

In other Lifecore Biomedical news, CEO Paul Josephs bought 17,000 shares of the stock in a transaction dated Wednesday, January 8th. The shares were bought at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the purchase, the chief executive officer now directly owns 559,717 shares of the company’s stock, valued at approximately $3,212,775.58. This trade represents a 3.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 32.20% of the stock is currently owned by corporate insiders.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.